Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol is an experimental small molecule compound with the molecular formula C21H14F2N2O2 and a molecular weight of approximately 364.35 g/mol. It has been studied as a ligand in structural biology and crystallography experiments involving receptor tyrosine kinases, specifically basic fibroblast growth factor receptor 1 (FGFR1). The compound is not approved for clinical use and has no known indications or completed clinical trials. Its primary relevance to date is as a tool compound for research into FGFR1 structure and function.[1][4][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol.